World British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to its lung medicines division that has been hit by generic competition. 03 May 2019 01:26AM Bookmark REUTERS: British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signaling a possible boost to its lung medicines division that has been hit by generic competition.The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta. However, GSK said Trelegy Ellipta did not meet its secondary goal.The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older … [Read more...] about GSK’s Trelegy Ellipta meets key goal in late-stage asthma study